Safety and Efficacy of Lotilaner Ophthalmic Solution (0.25%) in Treating Demodex Blepharitis: Pooled Analysis of Two Pivotal Trials.

Introduction: Lotilaner ophthalmic solution (0.25%) is the first United States Food and Drug Administration (US FDA)-approved drug for treating Demodex blepharitis. In pivotal trials, it was found to be well tolerated and demonstrated a significant reduction in collarettes and mite density after a 6-week treatment regimen.

Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Rationale: Osteoporosis is an abnormal reduction in bone mass and bone deterioration, leading to increased fracture risk. Alendronate belongs to the bisphosphonate class of drugs, which inhibit bone resorption by interfering with the activity of osteoclasts (bone cells that break down bone tissue). This is an update of a Cochrane review first published in 2008.

A rare case of primary testicular follicular lymphoma in a pediatric patient.

Testicular follicular lymphoma (TFL) is an exceedingly rare lymphoma that typically occurs in young male patients and is now recognized as a distinct diagnostic entity in the International Consensus Classification. TFL shows some clinicopathologic and genetic overlap with pediatric-type follicular lymphoma (PTFL). We report a case of TFL occurring in an otherwise healthy 4-year-old boy who presented with painless scrotal swelling.

Risk factors affecting polygenic score performance across diverse cohorts.

Apart from ancestry, personal or environmental covariates may contribute to differences in polygenic score (PGS) performance. We analyzed the effects of covariate stratification and interaction on body mass index (BMI) PGS (PGS) across four cohorts of European (N = 491,111) and African (N = 21,612) ancestry. Stratifying on binary covariates and quintiles for continuous covariates, 18/62 covariates had significant and replicable R differences among strata.

Development and Implementation of Digital Health Tools in Radiation Oncology: A Rapid Review.

A rapid review of 21 studies into 20 unique digital health tools found significant benefits to utilizing the following 4 categories of tools: (1) educational videos increased patient knowledge of radiotherapy (RT) and reduced treatment-related anxiety; (2) extended reality tools improved patient understanding of RT and reduced anxiety, with virtual reality coaching enhancing tumor motion reproducibility during CT simulation; (3) digital patient engagement tools helped patients manage treatment symptoms, increased health literacy, and improved quality of life; (4) an electronic feedback form decreased patient anxiety and increased RT knowledge. Most interventions were single-use and implemented before the start of RT.